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1. Introduction 
Calcific aortic stenosis (AS) is the most common form of degenerative heart valve disease in 
developed countries. AS predominantly affects the elderly with a prevalence of 4% in 
people over the age of 80 years. With increasing longevity and an ageing population the 
absolute number of people afflicted with AS is set to rise. The clinical course of the disease is 
insidious at first (Ross & Braunwald, 1968), but is followed by rapid progression once 
symptoms of congestive cardiac failure, angina and syncope develop (Cheitlin et al., 1979; 
Otto et al., 1989; Davies et al., 1991; Peter et al., 1993). If left untreated mortality exceeds 50% 
at two years (Kelly et al., 1988; Turina et al., 1987) and AS is, therefore, set to become a major 
public health problem in the ensuing decades. 
Aortic valve replacement (AVR) has been the gold standard intervention for AS for more 
than 40 years (Charlson et al., 2006) and over 60,000 procedures are performed annually in 
the European Union. However, one third of patients are denied access to surgery, often due 
to their advanced age (Iung et al., 2003, 2005). Percutaneous balloon valvuloplasty was 
heralded initially as a promising breakthrough for high-risk symptomatic patients with AS 
(Cribier et al., 1986). However, long-term follow-up has yielded unacceptable rates of 
restenosis and poor event-free survival (Otto et al., 1994; Lieberman et al., 1995). Balloon 
valvuloplasty is now recommended only as a bridge to emergency AVR or in the palliation 
of symptoms in the frailest of patients (Ussia et al., 2010; Zahn et al., 2011). 
Transcatheter aortic valve implantation (TAVI) has recently emerged as an effective 
therapeutic alternative to conventional AVR for high-risk AS patients. TAVI was developed 
initially in porcine models (Anderson et al., 1992), but it took a decade for this technology to 
be translated to humans (Cribier et al., 2002). Initially, an antegrade transseptal approach 
was used, but this has now been superseded by transapical (Ye et al., 2006; Webb et al., 2007) 
and retrograde percutaneous techniques (transarterial or transaxillary) (Webb et al., 2006). 
The range of different approaches has increased the feasibility of TAVI in patients with 
relative contraindications, such as extensive peripheral vascular disease, porcelain aorta and 
thoracic radiotherapy. TAVI is also less invasive than open AVR and permits replacement of 
the native diseased valve in the beating heart without the need for sternotomy and 
cardiopulmonary bypass. Consequently, TAVI may be less influenced by a patient’s 
comorbidities and may facilitate faster recovery. 
A multidisciplinary team consisting of interventional cardiologists, cardiothoracic surgeons, 
cardiac anesthetists and imaging specialists is best suited to make decisions between open 
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AVR, TAVI and medical management. This ensures apt patient selection and prompt 
delivery of care. There has been a rapid expansion in the number of studies investigating 
TAVI in the last five years and these have demonstrated promising results in terms of 
feasibility, safety and efficacy. Doubts remain, however, about the long-term durability of 
TAVI implants and their disposition to valvular dysfunction and about the need for 
reoperation. This chapter discusses the selection of patients for TAVI, techniques of 
implantation, clinical and patient-reported outcomes and future directions of research and 
development. 
2. Patient selection 
Clinical decision-making in patients with AS is complex and from the outset requires a 
patient-centered approach and the involvement of a multidisciplinary team. Open AVR is 
associated with excellent clinical and functional outcomes in large modern series (Brown et 
al., 2009; Malaisrie et al., 2010) and, at present, is the gold standard intervention for patients 
with severe, symptomatic AS (Bonow et al., 2006). However, patient selection is 
controversial. Central to the controversy is a belief that elderly patients, especially those 
with major comorbidities or with complications of AS (e.g. left ventricular dysfunction) 
present too great an operative risk or lack sufficient life expectancy to justify surgical AVR 
(Asimakopoulos et al., 1997; Connolly et al., 2000; Elayda et al., 1993; Monin et al., 2003). AVR 
is highly invasive and requires sternotomy, cardiopulmonary bypass, hypothermic 
cardioplegic arrest and cardiotomy. These factors expose patients to certain deleterious 
effects on end-organs, including ischemia, reperfusion injury, systematic inflammatory 
response, surgical trauma and oxidative stress (Anselmi et al., 2004). In 2003, the Euro Heart 
Survey on Valvular Heart Disease reported that approximately one third of patients with 
severe, symptomatic AS are denied potentially life-saving surgery because of concerns over 
age, comorbidities and likely longevity (Iung et al., 2003, 2005). This is in spite of some recent 
series demonstrating promising safe and efficacious outcomes for AVR in octogenarians 
(Melby et al., 2007; Florath et al., 2010; Leontyev et al., 2009). 
TAVI is a novel approach to AS in high-risk patients and provides an alternative 
management option that negates invasive surgery. TAVI is still in its infancy in terms of the 
operator learning curve, the level of technological development of the implants and the 
evidence base required to determine which patients are most likely to benefit. At present, 
TAVI is recommended only for patients not considered suitable for open AVR and who 
have a life expectancy of greater than one year (Vahanian et al., 2008). This section will 
describe some of the available patient risk stratification tools used for clinical decision-
making in AS, the current indications and contraindications to TAVI, and possible 
diversification in the use of minimally invasive aortic valve interventions. 
2.1 Risk stratification tools 
The choice between treatment options in AS should ideally be based upon a shared decision 
between the fully informed patient and a multidisciplinary team who guide the patient to 
the required information. Part of this process includes an assessment by physicians of the 
likely risk of mortality and serious morbidity of undergoing open AVR. A range of scoring 
systems have been developed that are designed to assist surgeons in such risk stratification 
(Ambler et al., 2005; Edwards et al., 2001; Florath et al., 2003; Hattler et al., 1994; Higgins et al., 
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1992; Nashef et al., 1999; Nowicki et al, 2004; O’Brien et al., 2009; Parsonnet et al., 1989; Pons 
et al., 1997; Roques et al., 1995; Roques et al., 1999; Tremblay et al., 1993; Tu et al., 1995). These 
systems are usually derived from multivariate analyses of preoperative and operative 
variables believed to influence outcomes in large cohorts of cardiothoracic patients. Risk 
stratification tools may be either generic for all open cardiothoracic procedures or specific to 
heart-valve interventions. The focus of this subsection is to discuss some of the widely used 
risk stratification tools. 
The Parsonnet score was one of the first mortality indicators developed to calculate average 
risk estimates of death in adult cardiothoracic patients (Parsonnet et al., 1989). The model 
allocates “additive” points for 14 risk factors associated with perioperative mortality, which 
are subsequently used to assign a percentage probability of death. The factors include 
female gender, obesity, diabetes, hypertension, low ejection fraction, increased age, first or 
second reoperation, preoperative intra-aortic balloon pump, emergency presentation from 
the cardiac catheter laboratory, dialysis dependency, catastrophic clinical state, valve 
surgery and combined valve surgery and coronary artery bypass grafts (CABG). In addition 
to overestimating mortality in high-risk cases, the Parsonnet score has been criticized for 
being subjective and including some factors that are now known not to be linked to early 
postoperative death (Gabrielle et al., 1997). The Parsonnet score also omits other potentially 
important factors, such as the urgency of surgery, which is widely considered to be strongly 
associated with perioperative outcome (Wynne-Jones et al., 2000). 
The Parsonnet score has been superseded by the European System for Cardiac Operative 
Risk Evaluation (EuroSCORE). The EuroSCORE was developed by analyzing survival 
outcomes for 19,030 cardiac surgical patients in eight European countries (Roques et al., 
1999). Logistic regression was used to reduce a list of 97 potential postoperative mortality 
risk factors to 18 independent variables with odds ratios of >1 predictive of death. It bears 
many similarities to the Parsonnet system and involves calculation of percentage predicted 
mortality by addition of points ascribed to various risk factors to produce an “additive” 
mortality score (Table 1). For AVR, the EuroSCORE study reported an overall procedural 
mortality of 6% and mortality in the absence of risk factors of 1.1%. The precision and 
accuracy of the EuroSCORE has been demonstrated in numerous studies (Kobayashi et al, 
2009; Wendt et al., 2010), but it has several limitations that compromise its validity in 
sufferers of severe, symptomatic AS. First, the data is derived from patients undergoing 
cardiac surgery for heterogeneous indications, including a high percentage of cases of 
isolated coronary artery bypass grafts (63.9%). Risk factors are, therefore, not specific to 
AVR. Secondly, there is evidence that the EuroSCORE overestimates mortality in high-risk 
patients or is inaccurate in those with unusual combinations of risk factors (Brown et al., 
2008; Dewey et al., 2008). This can exaggerate mortality estimates and may mean that 
patients are not offered AVR, even if they are potential surgical candidates. The ”logistic” 
EuroSCORE has since been introduced for use in high-risk individuals because of its greater 
accuracy (Roques et al., 2003). Nonetheless, it still suffers from problems with clinical 
relevance. Consequently, the ”additive” and ”logistic” algorithms have been combined to 
form the ”modified” EuroSCORE (Nissinen et al., 2009). Further problems with the 
EuroSCORE relate to the fact that it does not take into account local institutional outcomes 
(Vahanian et al., 2008) or characteristics unique to certain AS patients (e.g. previous CABG 
with patent grafts, porcelain aorta or thoracic radiotherapy). These factors may confer 
additional risks that can alter the choice of intervention at the institutional level (Robes-
Cabau et al., 2010). 
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Variable Odds ratio ± 
Standard error
P-value Additional % 
mortality 
Age per 5 years after 60 years 1.1 ± 0.007 0.001 1 
Female gender 1.4 ± 0.128 0.001 1 
Preoperative creatinine > 200 μmol/L 1.9 ± 0.256 0.001 2 
Extracardiac arteriopathy 1.9 ± 0.376 0.001 2 
Pulmonary disease 1.6 ± 0.284 0.006 1 
Neurological dysfunction 2.3 ± 0.584 0.001 2 
Previous cardiac surgery 2.6 ± 0.324 0.001 3 
Recent myocardial infarction 1.6 ± 0.208 0.001 2 
LVEF 30-50% 1.5 ± 0.138 0.001 1 
LVEF < 30% 2.5 ± 0.340 0.001 3 
Pulmonary hypertension (> 60 mmHg) 2.0 ± 0.423 0.001 2 
Active endocarditis 2.5 ± 0.678 0.001 3 
Unstable angina 1.5 ± 0.202 0.001 2 
Emergency operation 2.8 ± 0.440 0.001 2 
Critical perioperative condition 2.2 ± 0.319 0.001 3 
Ventricular septal rupture 3.8 ± 1.735 0.002 4 
Noncoronary surgery 1.6 ± 0.170 0.001 2 
Thoracic aortic surgery 3.2 ± 0.650 0.001 3 
Table 1. Risk factors for mortality in patients undergoing cardiac surgery based on the 
EuroSCORE dataset (reproduced from Roques et al., 1999; LVEF = left ventricular ejection 
fraction) 
Recently, emphasis has been placed on developing risk stratification tools with greater 
reliability and validity in patients with valvular heart disease. The Ambler score was 
published in 2005 after it had been field-tested in 32,839 consecutive patients undergoing 
heart valve surgery in the UK (Ambler et al., 2005). It identified 14 risk factors associated 
with in-hospital mortality (operative priority, age, renal failure, operation sequence, ejection 
fraction, concomitant tricuspid valve surgery, type of valve surgery, concomitant CABG, 
body mass index, preoperative arrhythmia, diabetes, gender, and hypertension). Its 
development involved robust methodology in a large cohort of patients, but it has not been 
widely adopted, perhaps because of concerns over external validity in non-UK populations. 
The Society of Thoracic Surgeons has since built on the advantages of the Ambler score by 
producing a tool that assists in predicting nine different postoperative variables (STS-
PROM; O’Brien et al., 2009). These are mortality, permanent stroke, renal failure, prolonged 
ventilation, deep sternal wound infection, reoperation, a composite endpoint of mortality 
and major morbidity, and short and prolonged postoperative stay. In addition to extending 
predictive models to several causes of major morbidity, the STS-PROM has been shown to 
be more reliable than the EuroSCORE in estimating mortality in high-risk patients (Dewey et 
al., 2008). At present, most major studies involving the selection of patients for TAVI use the 
EuroSCORE and STS-PROM. 
2.2 Indications and assessment of suitability for TAVI 
TAVI is recommended for use only in patients with calcified pure or predominant AS, and 
not in cases where aortic regurgitation is the primary pathology. In 2008, the European 
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Association of Cardiothoracic Surgery (EACTS), the European Society of Cardiology (ECS), 
and the European Association of Percutaneous Cardiovascular Intervention (EAPCI) issued 
a joint statement describing a four-stage assessment procedure to be undertaken to 
differentiate between treatment options in AS and to confirm suitability for TAVI (Vahanian 
et al., 2008). The first stage involves echocardiography to confirm the diagnosis and severity 
of AS, and to exclude significant aortic regurgitation. TAVI is presently restricted to cases of 
severe AS because of the proven effectiveness of AVR. The inclusion criteria of well-
designed trials offer some insight into the definition of the severity of AS at 
echocardiography. In THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve 
Trial, patients were randomized to interventions (AVR, TAVI, or medical management) only 
if proved to have an aortic valve area (AVA) of < 0.8 cm2 (or an indexed AVA of < 0.6 cm2) 
or a peak aortic valve gradient of > 40 mmHg (or a peak velocity of > 4.0 m/s) (Leon et al., 
2010). Analogous values should be used when deciding whether TAVI is appropriate for 
particular individuals, and many studies have used similar cut-offs to assign patients to 
treatment with TAVI (Clavel et al., 2010; Malaisrie et al., 2011; Zahn et al., 2011). In certain 
circumstances, low-dose dobutamine echocardiography may also be of value to distinguish 
between severe AS and the rare “pseudo-severe” AS, especially in patients with a low left 
ventricular (LV) ejection fraction and a low aortic transvalvular gradient (Bonow et al., 2006; 
Vahanian et al., 2007). 
The second stage in TAVI assessment involves an accurate evaluation of the presenting 
symptoms and clinical findings. Current guidelines recommend that TAVI should be 
undertaken only when symptoms are directly attributable to AS (Vahanian et al., 2008). 
Several concurrent diseases may mimic the symptom profile of AS, such as chronic 
obstructive pulmonary disease or pulmonary hypertension. A clear history and chronology 
of the symptoms of dyspnea, chest pain, and syncope are, therefore, required, and when the 
diagnosis is uncertain, biomarkers of increased myocardial mechanical load, such as beta-
type natriuretic peptide (BNP), may be of value (Vahanian et al., 2010). Clinical confirmation 
of the diagnosis is necessary because of concerns over the long-term durability of TAVI 
devices. 
Arguably, the most complex stage when assessing patients with AS is deciding between 
AVR, TAVI, and conservative management. This requires multidisciplinary team evaluation 
of the possible risks of open AVR and TAVI, predicted life expectancy, and quality of life. To 
evaluate the risk of operative mortality and serious morbidity, it is recommended that 
clinical judgment be combined with the scores from two risk stratification tools (Vahanian et 
al., 2008). This combination allows for an objective risk assessment, while ensuring that 
additional factors not included in risk stratification tools (e.g. porcelain aorta, previous 
CABG with patent grafts, previous thoracic radiotherapy, or liver cirrhosis) are taken into 
account. Typically, mortality > 20% calculated using the logistic EuroSCORE or > 10% using 
the STS-PROM are seen as high-risk indicators that would preclude open AVR in most cases 
(Leon et al., 2010; Vahanian et al., 2008; Vahanian et al., 2010). However, scoring systems 
should not necessarily be viewed as a substitute for experienced clinical judgment or 
informed patient choice. As part of the multidisciplinary approach, it is recommended that 
patient-reported outcomes, such as health-related quality of life (HRQL), be considered. The 
use of validated HRQL tools should be combined with clinical parameters to assist in the 
shared decision-making process (Lee et al., 2006; Vahanian et al., 2008). 
The final stage before TAVI insertion in high-risk patients with severe, symptomatic AS 
includes an assessment of the feasibility and contraindications to TAVI. The first-line 
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investigation is coronary angiography to identify occlusive lesions in need of 
revascularization. Lesions amenable to percutaneous angioplasty and stenting can be 
treated either before, during, or after TAVI. The decision on the timing of revascularization 
is complex and should be tailored to individual cases. Patients with proximal coronary 
stenoses may not be appropriate candidates for TAVI (Vahanian et al., 2008) because of 
concerns over occlusion of the coronary ostia by the device (Gogas et al., 2011; Gurvitch et 
al., 2011). If coronary stenoses can be managed only surgically, then a choice must be made 
between high-risk AVR and the poor outcomes associated with medical management and 
balloon valvuloplasty. 
Determining the diameter of the aortic annulus is a prerequisite to TAVI operational 
planning and ensures that an appropriately sized implant is deployed. This can be 
accomplished using either invasive techniques (e.g. aortography as part of balloon 
valvuloplasty) or noninvasive imaging modalities (e.g. echocardiography, multislice high 
resolution computed tomography, or magnetic resonance imaging) (Tops et al., 2008; 
Vahanian et al., 2008). Transthoracic echocardiography has been shown to underestimate the 
size of the aortic annulus, and should be supplemented with transesophageal 
echocardiography when borderline sizes result in doubt over the feasibility of the procedure 
(Moss et al., 2008). Accurate sizing prior to TAVI is necessary to prevent paravalvular leak 
and rupture of the aortic annulus. The peripheral vasculature must also be imaged, in 
particular the aortic arch, descending aorta, and iliac vessels. This can be achieved with 
either formal or computed tomography angiography. Gadolinium magnetic resonance 
angiography is an alternative in patients with impaired renal function. Both the size and 
tortuosity of the vessels are important because they affect access and help to decide between 
the transarterial and transapical approaches. 
2.3 Contraindications to TAVI 
For technical reasons, TAVI is not possible in all high-risk patients with AS, but using 
different access ports has increased the number of patients who can be successfully treated. 
General contraindications to TAVI include: 
• Aortic annulus diameter < 18 mm or > 25 mm for balloon expandable implants, and < 
20 mm or > 27 mm for self-expandable devices. 
• Bicuspid aortic valves that may lead to incomplete deployment of the device and 
paravalvular leak (Zegdi et al., 2008). 
• Heavy asymmetrical aortic valve calcification because of concerns over occlusion of the 
coronary ostia (Webb et al., 2006). 
• Low position of the coronary ostia (< 8 mm from the aortic annulus). 
• Aortic root diameter of > 45 mm at the aorto-tubular junction for self-expandable 
devices. 
• Severe organic mitral regurgitation. 
• LV thrombus. 
There are a number of contraindications specific to the type of approach. For the 
transfemoral approach, these are: 
• Severely calcified or tortuous iliac arteries. 
• Iliac artery diameter of < 6 mm to < 9 mm, depending on the type of device used. 
• Previous aorto-femoral bypass grafts. 
• Severely angulated aorta or atherosclerotic aortic arch. 
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• Transverse ascending arch (for balloon expandable devices). 
• Aortic aneurysm with extensive mural thrombus. 
• Coarctation of the aorta. 
For the transapical approach, contraindications are: 
• Previous surgical patch of the left ventricle (e.g. Dor procedure). 
• Calcified pericardium. 
• Severely impaired respiratory function. 
• Inability to access the apex of the left ventricle due to anatomical constraints (e.g. chest 
deformity). 
2.4 Expanding the role of TAVI 
Implants used in open AVR are either mechanical or bioprosthetic. Mechanical valves have 
the advantage of long-term durability, but require life-long anticoagulation with the 
associated risk of major hemorrhage. Patients fitted with bioprosthetic valves do not need to 
take anticoagulants, but the chance of valvular degeneration increases with time. 
Mechanical valves are, therefore, usually restricted to younger patients, while bioprosthetic 
implants are used more frequently in the elderly population, in which the chance of 
surviving to revision surgery is low. Nonetheless, valvular degeneration occurs in a 
proportion of patients, and treatment typically necessitates revision AVR, which is 
inherently high-risk. 
In 2008 the first case of valve-in-valve (VIV) TAVI was reported in an 82-year-old patient 
with valvular degeneration of a Carpentier-Edwards Perimount aortic valve (Walther et al., 
2008a). This pioneering procedure was performed off-pump using a transapical approach. 
VIV is an attractive technique that involves placing the implant within the previous 
prosthetic valve, abutting the degenerated valve leaflets up against the aortic annulus. 
Typically, transapical access is preferred for VIV procedures, although reports have recently 
emerged describing the transaxillary (Sharp et al., 2010) and trans-subclavian approaches 
(Olsen et al., 2010). The Edwards SAPIEN valve may be better suited to VIV implantation 
(Kempfert et al., 2010), although the Medtronic CoreValve system has been successfully used 
(Khawaja et al., 2010). 
There are promising early results for VIV, although reports tend to be anecdotal or restricted 
to small case series, and no large comparative studies are currently available (Ferrari et al., 
2010; Kempfert et al., 2010; Khawaja et al., 2010; Olsen et al., 2010; Sharp et al., 2010). 
Transvalvular gradients post-procedure are usually satisfactory (Ferrari et al., 2010; 
Kempfert et al., 2010; Walther et al., 2008a), while residual aortic regurgitation tends to be 
minimal (Kempfert et al., 2010). Severe paravalvular leak is a feared complication of TAVI, 
but several authors have described its successful treatment with rescue VIV (Rodes-Cabau et 
al., 2009; Taramasso et al., 2010). Concerns exist over excessive transvalvular gradients of 
VIV implants in patients fitted previously with small-diameter prostheses (e.g. < 23 mm in 
diameter) (Ferrari et al., 2010). For TAVI, the diameter of the device is typically oversized by 
10-20% in relation to the aortic annulus, but for VIV undersizing is preferred, which is 
currently not feasible in some patients with small annuli because of the size of available 
implants. At present, VIV is off-label in many countries, including the United States. 
TAVI is minimally invasive and has consistently demonstrated promising outcomes in high-
risk patients (see Section 4). In the future, it is likely that the indications for TAVI will be 
expanded to include younger patients at low operative risk. However, caution is advised for 
www.intechopen.com
 Aortic Valve 
 
228 
several reasons. Despite the lack of randomized clinical trial (RCT) data to support the use 
of open surgery, AVR has shown excellent long-term clinical, hemodynamic and functional 
outcomes in low-risk AS patients (Hammermeister et al., 1993; Myken et al., 1995; Peterseim 
et al., 1999). Modern RCTs comparing AVR to medical management would be unethical 
because of a lack of clinical equipoise, leading to appropriate patients being denied access to 
a treatment with proven long-term effectiveness. The durability of TAVI implants is still a 
concern due to the technique’s relative age. More work to characterize the long-term 
outcomes of TAVI is necessary before it is offered routinely to low-risk patients. 
3. Devices and techniques 
The technology that underpins TAVI has evolved dramatically in the last two decades since 
its inception in animal models (Anderson et al., 1992) and later realization in humans 
(Cribier et al., 2002). At present, there are two major producers of TAVI devices that are used 
routinely in clinical practice (Edwards Lifesciences, Irvine, CA, USA & Medtronic Inc., 
Minneapolis, MN, USA). Technological development of both implants is on-going, and each 
has its advantages and disadvantages in different clinical situations. There are a variety of 
access sites through which TAVI can be performed, including directly through the left 
ventricular apex as well as the femoral, axillary and subclavian arteries. This section will 
describe the features of current and future implants and the techniques required for their 
implantation. 
3.1 TAVI devices 
The prototypic Cribier-Edwards TAVI device was one of the earliest deployed in humans. It 
has now been replaced by newer Edwards Lifesciences designs, including the SAPIEN 
transcatheter heart valve (THV) (Figure 1) and, more recently, by the SAPIEN XT. The 
SAPIEN devices are constructed from bovine pericardial leaflets mounted on a cobalt-
chromium frame. The device is balloon expandable and manufactured in 23-mm and 26-mm 
sizes, which allows it to be used in patients with aortic annulus diameters of between 18 mm 
and 25 mm. As the implant is deployed (Figure 2), it fixes within the aortic annulus without 
the need for stabilization in the ascending aorta (Webb and Cribier, 2010). Early devices 
required large-caliber delivery systems; however, the latest versions can be deployed 
through vessels with a minimum diameter of 6 mm. Transapical and percutaneous 
approaches can both be used with the SAPIEN system. 
The Medtronic CoreValve consists of a porcine pericardial valve mounted on a nitinol self-
expandable metal frame. It is considerably longer than SAPIEN devices (53-55 mm versus 
15-17 mm) and anchors distally in both the ascending aorta and supracoronary region. The 
CoreValve can be deployed through an access channel with a minimum diameter of 6 mm 
and can be used in patients with an aortic annulus diameter of between 20 mm and 27 mm. 
The device is not licensed for transapical use, but when used via a peripheral access vessel, 
it is associated with greater hemodynamic stability during deployment, more forgiving 
positioning and can be retrieved if sited incorrectly (Webb and Cribier, 2010). Despite this, 
the CoreValve suffers from a high incidence of post-procedural heart block, which requires 
prolonged cardiac monitoring, and pacemaker insertion is necessary in up to 40% of cases. 
A number of next generation TAVI devices are currently undergoing clinical testing (Falk et 
al., 2009; Low et al., 2008; Schofer at al., 2008; Treede et al., 2010). These are based generally 
on the self-expandable CoreValve system and allow for smaller caliber delivery systems,  
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Fig. 1. The Edwards SAPIEN Transcatheter aortic valve (Photo courtesy of Edwards 
Lifesciences) 
 
 
Fig. 2. Transcatheter aortic valve crimped onto the introducing catheter (Photo courtesy of 
Edwards Lifesciences) 
retrieval and greater accuracy when deployed. Examples include the DirectFlow (Direct 
Medical Flow Inc., Santa Rosa, CA, USA), Lotus (Boston Scientific Inc., Natick, MA, USA) 
and HLT (Heart Leaflet Technologies Inc., Maple Grove, MN, USA). Other systems 
incorporate features that allow fixation in the supracoronary aorta (Accurate, Symentis Inc., 
Lausanne, Switzerland; St Jude, St Jude Medical Inc., St. Paul, MN, USA) and anatomical 
guides to demonstrate the position of the native valve and coronary arteries, thus facilitating 
deployment (Engager, Medtronic Inc., USA; JenaClip, JenaValve Inc., Munich, Germany). At 
present, little is known about these novel valves in terms of their efficacy, safety, feasibility, 
and long-term durability. Further work is required to characterize their outcomes before 
they can be recommended for use in routine clinical practice. 
3.2 Percutaneous access 
Initial reports of TAVI used a transseptal approach with access via the venous system (Cribier 
et al., 2002). This route was technically challenging and not reproducible. Retrograde arterial 
approaches are now much more widely used. Access is gained typically through the femoral 
www.intechopen.com
 Aortic Valve 
 
230 
artery (Webb et al., 2006). The axillary, subclavian, and retroperitoneal iliac arteries, as well as 
the ascending aorta, have also been successfully used (Webb and Cribier, 2010). Cut-down to 
expose the arteries is sometimes done: this improves the ease of cannulation of the vessels and 
ensures safe closure. In such cases, the patient is usually anesthetized, which confers 
additional risks in this frail population. Percutaneous arterial puncture and suture closure is 
now the standard of care and can be completed safely under sedation (De Jaegere et al., 2007; 
Vavuranakis et al., 2010). After arterial puncture, aortography is done to characterize the 
coronary vessels, diseased valve, and aorta. Balloon valvuloplasty is then used to dilate the 
native valve under rapid ventricular pacing, which decreases cardiac output while the balloon 
is inflated. Between periods of rapid pacing, the blood pressure must be allowed to normalize. 
Intraoperative imaging, including aortography, transesophageal echocardiography, and 
fluoroscopy, is used to identify the optimal position for the new valve. Once this has been 
determined, the valve is deployed. Rapid ventricular pacing is required for balloon 
expandable devices (Figure 3), but not for self-expandable systems. Post-procedural 
echocardiography and aortography are done to check the position and function of the implant, 
the patency of the coronary vessels, and the presence of early complications (e.g. aortic 
regurgitation, paravalvular leak, aortic dissection, hemopericardium). It is recommended that 
patients are nursed postoperatively in the cardiac intensive care unit with invasive monitoring. 
 
 
Fig. 3. Showing the retrograde approach and balloon inflation (black arrow) of the trans-
catheter aortic valve (white arrow) (Photo courtesy of Edwards Lifesciences) 
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3.3 Transapical approach 
Transapical TAVI involves inserting the valve device in an antegrade fashion through the 
anterolateral chest wall and apex of the left ventricle (Figure 4). This is done under general 
anesthesia with cardiopulmonary bypass (CPB) on standby. CPB is usually established 
through the femoral vessels if required. The site of the incision is determined by 
transthoracic echocardiography. After the chest cavity has been entered, the pericardium is 
opened and secured to the thoracic wall. Pacing wires are then attached to the myocardium 
to facilitate rapid ventricular pacing. Two purse-string sutures are inserted into the apex, 
and an introducer sheath is passed between them into the left ventricle. Guided by imaging, 
the implant is positioned across the native valve and then deployed using balloon inflation 
and rapid ventricular pacing. Postoperatively, the patient should be nursed in an intensive 
care unit for at least 24 hours. Transapical TAVI involves a thoracotomy, and for this reason 
is not recommended for patients with severe respiratory disease that precludes one-lung 
ventilation. In rare instances, a mini-sternotomy has been combined with retrograde 
transaortic TAVI, where the device is inserted via the ascending aorta (Latsios et al., 2010). 
This technique is reserved for patients with no other access sites. 
 
 
Fig. 4. Trocar being antegradely introduced through the apex of the left ventricle (Photo 
courtesy of Edwards Lifesciences) 
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3.4 Service structure 
The performance of TAVI should be restricted to a small number of high-volume centers 
with readily available input from specialist cardiothoracic surgeons, interventional 
cardiologists, cardiac anesthetists, intensivists and perfusionists. The center must be 
proficient in dealing with both open and percutaneous valvular interventions in high-risk 
populations. Familiarity with the procedure and multidisciplinary management are likely to 
improve the rate of successful implantation and limit the number of complications. 
Furthermore, if complications do occur, they can be managed without the delay associated 
with transferring patients to another institution. Interventional cardiologists should have 
experience of a range of percutaneous valvular interventions, large-bore peripheral 
cannulation, and percutaneous suture closure. Cardiac surgeons should routinely perform 
complex open valvular procedures and be able to offer rescue or salvage surgery when 
complications arise. Bleeding from damaged peripheral vessels is not infrequent following 
TAVI, so it is also advantageous to also have onsite access to vascular surgeons and 
radiologists trained in either open or endovascular arterial repair. 
4. Outcomes 
Outcomes are events that are either present or absent in study participants at specific time 
points after an intervention or exposure. They can be clinical, patient-reported, healthcare 
economic, composite, or surrogate. Studies investigating outcomes of interventions for 
aortic valve pathology concentrate on the safety, feasibility, efficacy, and durability of 
treatment options. Safety is typically assessed with clinical measures, such as operative 
morbidity and mortality. Feasibility describes whether the procedure can be accomplished 
successfully without recourse to alternative treatment. Efficacy is defined as whether an 
intervention works in those who receive it. For aortic valve therapies, it is usually based on 
echocardiographic findings and functional outcomes, such as the New York Heart 
Association (NYHA) classification and HRQL tools. Durability includes long-term outcomes 
such as prosthesis failure, reoperation, and survival. High quality studies, including 
randomized controlled trials (RCTs), are required to evaluate these outcomes in patients 
with severe AS and to inform treatment choices between open AVR, TAVI, balloon 
valvuloplasty, and medical management. This section will summarize outcomes from 
studies that have investigated the use of TAVI. 
4.1 Evidence from the PARTNER Trial 
RCTs are the gold standard study design for assessing surgical innovation. However, there 
is a paucity of well-designed surgical RCTs, which is in part due to specific methodological 
difficulties. Surgery is a complex intervention and is comprised of multiple events that 
interact together to affect outcomes. For example, perioperative mortality may be affected 
by patient factors (e.g. comorbidities), surgeon factors (e.g. skill and technique), anesthetic 
factors (e.g. quality of postoperative care) and service factors (e.g. number of nursing staff, 
rehabilitation services). If these factors are poorly controlled in an RCT, then confounding 
variables may result in bias. It is important that trials clearly predefine all aspects of the 
intervention in the study protocol and report protocol deviations in subsequent 
publications. The timing of surgical RCTs is also critical. RCTs undertaken too early in the 
development of a novel intervention may underestimate treatment effect magnitude as a 
consequence of operator learning-curve effects. RCTs undertaken too late after the 
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introduction of a procedure can be unethical because of a loss of equipoise. It is difficult to 
blind participants and clinicians in surgical RCTs due to differences in outward appearances 
of wounds, and because the surgeon will always know which procedure has been 
performed. This problem can be overcome by blinding outcome assessors and data analysts 
to the allocation sequence. Another problem with surgical RCTs relates to the fact that they 
are often costly to undertake, and follow-up needs to be long-term to identify late and rare 
events. 
The PARTNER Trial was the first RCT to compare outcomes between TAVI and other 
interventions for severe AS (Leon et al., 2010). The study consisted of two parallel, 
prospective, multicenter, randomized trials. The first of these (Cohort A) randomized to 
either TAVI or open AVR participants with severe AS who were considered high-risk for 
surgery (STS-PROM > 10% mortality risk or > 15% predicted 30-day mortality). In Cohort B, 
patients with severe AS and considered unsuitable for surgery (> 50% predicted 30-day 
mortality or a serious irreversible condition) were allocated to either TAVI or medical 
management, which included balloon valvuloplasty. The primary outcome measure in 
Cohort A was survival at one year. In Cohort B, the primary endpoint was initially survival 
for the duration of the study, although this was supplemented partway through the trial 
with a composite co-primary outcome of survival and time to first rehospitalization. 
Secondary outcome measures included: functional improvement in NYHA classification; 
freedom from major adverse cardiovascular and cerebrovascular events (MACCE); evidence 
of prosthetic valve dysfunction (hemolysis, infection, thrombosis, severe paravalvular leak, 
or migration); a six-minute walk test; length of hospital stay; total hospital days from the 
index procedure to one year postoperatively; HRQL at 30 days, six months, and one year; 
improvement in aortic valve area; and a composite of survival, recurrent hospitalization, 
and NYHA class. The eligibility criteria for the PARTNER Trial are listed in Table 2. 
To date only results from Cohort B have been published, with the findings of Cohort A 
expected in late 2011. Between May 2007 and March 2009, 358 consecutive patients with 
severe AS who were considered unsuitable for surgery (Cohort B) were enrolled at 21 
centers. Randomization allocated 179 patients to receive TAVI (Edwards SAPIEN device 
using the transfemoral approach) and 179 to be treated with medical management. 
Participants were followed-up for at least one year. The rate of death from any cause at one 
year post-randomization (primary endpoint) was 30.7% in those treated with TAVI and 
50.7% in those treated with medical care alone (hazard ratio: 0.55; 95% confidence interval: 
0.40 to 0.76; p < 0.001). The cardiovascular mortality rate one year after randomization was 
also lower in the TAVI group (20.5% vs. 44.6%; hazard ratio: 0.39; 95% confidence interval: 
0.27 to 0.56; p < 0.001). Furthermore, the composite endpoint of rate of death from any cause 
and rehospitalization at one year (co-primary endpoint) was 42.7% with TAVI compared 
with 71.6% with medical care alone (hazard ratio: 0.46; 95% confidence interval: 0.35 to 0.59; 
p < 0.001). 
Complications were observed more frequently in the TAVI arm of the trial. There was a 
greater incidence of cerebrovascular events after TAVI at both 30 days after randomization 
(6.7% vs. 1.7%, p = 0.03) and at one year (10.6% vs. 4.5%, p = 0.04). Patients who received 
TAVI were also more likely to suffer major bleeding or vascular complications. Despite this, 
30-day mortality was similar between groups. Patients treated with TAVI demonstrated 
marked improvements in functional outcomes: 74.8% of patients alive at one year in the 
TAVI arm were asymptomatic or had only mild symptoms (NYHA classes I or II), compared 
with 42.0% of surviving participants in the medical care alone group (p < 0.001). In addition, 
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Inclusion criteria for the PARTNER Trial: 
• Patients must have comorbidities such that the surgeon and cardiologist Co-Principle 
Investigators concur that the predicted risk of operative mortality is ≥ 15% and/ or a 
minimum STS-PROM score of 10. 
• Patient has senile degenerative aortic valve stenosis with echocardiographically 
derived criteria: mean gradient > 40 mmHg or jet velocity greater than 4.0 m/s or an 
initial aortic valve area of < 0.8 cm2. 
• Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by 
NYHA Functional Class II or greater. 
• The patient or the patient's legal representative has been informed of the nature of 
the study, agrees to its provisions, and has provided written informed consent as 
approved by the IRB of the respective clinical site. 
• The patient and the treating physician agree that the patient will return for all 
required post-procedure follow-up visits. 
Cohort B All candidates for Cohort B in this study must meet #2, 3, 4, 5 of the above 
criteria and: 
• The patient, after formal consults by a cardiologist and two cardiovascular surgeons, 
agrees that medical factors preclude operation, based on a conclusion that the 
probability of death or serious, irreversible morbidity exceeds the probability of 
meaningful improvement. Specifically, the probability of death or serious, 
irreversible morbidity should exceed 50%. 
Exclusion Criteria for the PARTNER Trial: 
• Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment 
(defined as Q wave MI, or non-Q wave MI with total CK elevation ≥ twice normal in 
the presence of CK-MB elevation or troponin level elevation (WHO definition). 
• Aortic valve was a congenital unicuspid or congenital bicuspid valve, or was 
noncalcified. 
• Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant 
aortic regurgitation > 3+). 
• Any therapeutic invasive cardiac procedure performed within 30 days of the index 
procedure, (or 6 months if the procedure was a drug eluting coronary stent 
implantation). 
• Pre-existing prosthetic heart valve in any position, prosthetic ring, severe mitral 
annular calcification, or severe (greater than 3+) mitral regurgitation. 
• Blood dyscrasias as defined: leukopenia (WBC < 3000 mm3); acute anemia (Hb < 9 
mg%); thrombocytopenia (platelet count < 50,000 cells/mm3); history of bleeding 
diathesis or coagulopathy. 
• Untreated clinically significant coronary artery disease requiring revascularization. 
• Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic 
support devices. 
• Need for emergency surgery for any reason. 
• Hypertrophic cardiomyopathy with or without obstruction. 
• Severe ventricular dysfunction with LVEF < 20%. 
• Echocardiographic evidence of intracardiac mass, thrombus or vegetation. 
• Active peptic ulcer or upper gastrointestinal bleeding within the prior 3 months. 
• A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), 
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or clopidogrel (Plavix), or sensitivity to contrast media, which cannot be adequately 
premedicated. 
• Native aortic annulus size < 18 mm or > 25 mm as measured by echocardiogram. 
• Recent (within 6 months) cerebrovascular accident or transient ischemic attack. 
• Renal insufficiency (creatinine > 3.0 mg/dL) or end-stage renal disease requiring 
chronic dialysis. 
• Life expectancy < 12 months due to noncardiac comorbid conditions. 
• Significant abdominal or thoracic aorta disease, including aneurysm (defined as 
maximal luminal diameter 5 cm or greater), marked tortuosity (hyperacute bend), 
aortic arch atheroma (especially if thick [> 5 mm], protruding, or ulcerated), 
narrowing of the abdominal aorta (especially with calcification and surface 
irregularities), or severe “unfolding” and tortuosity of the thoracic aorta. 
• Iliofemoral vessel characteristics that would preclude safe placement of 22F or 24F 
introducer sheath, such as severe calcification, severe tortuosity or vessels size 
diameter < 7 mm for 22F sheath or < 8 mm for 24F sheath. 
Table 2. Eligibility criteria for participants included in the PARTNER Trial (Leon et al., 2010) 
there was a significant improvement in the six-minute walk test in patients treated with 
TAVI, but not in those who received medical care alone. Echocardiography demonstrated a 
significant reduction in aortic valve area and transvalvular gradient at 30 days in patients 
receiving TAVI. Moreover, these findings were maintained at one year, which suggested 
that TAVI devices are durable at least into the medium term. 
Leon et al. (2010) concluded that medical care alone did not alter the course of severe AS in 
patients who were not candidates for surgery. Transfemoral TAVI was markedly superior to 
medical care alone in this high-risk cohort of patients, and TAVI improved the rates of all-
cause and cardiovascular mortality. This is emphasized by the fact that only five patients 
needed to be treated with TAVI to prevent one death in the first year of follow-up. The 
safety of TAVI was highlighted by the similar 30-day mortality rate to medical care alone, 
despite a greater risk of vascular damage and bleeding, which were attributed to the large 
bore femoral access sheaths required in early versions of the Edwards SAPIEN heart-valve 
system. It is likely that future use of lower profile sheaths will reduce the incidence of 
vascular damage. Stroke rates were greater with TAVI and are the likely consequence of 
atherosclerotic emboli released during deployment of the valve. Less traumatic TAVI 
systems and novel cerebrovascular protection devices may help limit the incidence of stroke. 
It is noteworthy that increased survival was associated with improved function: patients 
treated with TAVI not only lived longer but also had fewer symptoms. Transfemoral TAVI 
is the current standard of care in patients who are not considered candidates for open AVR. 
The PARTNER Trial provides the best evidence yet to support the use of TAVI, although it 
is important to interpret the findings of Cohort B in the light of several limitations. The first 
of these relates to external validity: the PARTNER Trial was predominantly explanatory 
rather than pragmatic and had strict eligibility criteria (Table 2). Consequently, the results 
should not be extrapolated to patients with characteristics different from those enrolled in 
the trial, such as patients with peripheral vascular disease or severe LV dysfunction and 
those requiring coronary artery bypass grafts. Furthermore, the trial investigated only the 
transfemoral approach with a single device (Edwards SAPIEN), which has now been 
superseded by newer prostheses. Methodologically the trial is limited by poor reporting of 
randomization, allocation concealment, and blinding, while there is evidence of selective 
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reporting of outcomes and the introduction of a co-primary outcome during the conduct of 
the trial. One final observation is that the trial offers only limited information on the long-
term durability of TAVI prostheses. Additional long-term randomized controlled trials are 
warranted, the results of which, together with the results of Cohort A, will offer some 
insight into the relative efficacy of TAVI and open AVR in high-risk patients. 
Since the first report of TAVI almost a decade ago, there has been an explosion in the 
number of related publications. Most of these are retrospective case series or comparative 
studies contrasting different approaches (transapical vs. transfemoral) or devices (Medtronic 
CoreValve vs. Edwards SAPIEN). Although the publications do not provide the same level 
of evidence as RCTs and are open to selection and recall bias, it is worth considering their 
findings because of their number. The next section summarizes the support or otherwise for 
TAVI from nonrandomized studies in terms of feasibility, safety, efficacy, and durability. 
4.2 Feasibility of TAVI 
The feasibility of TAVI can be assessed by considering the procedural success rate, defined 
as whether the implant was successfully deployed without immediate complications or the 
need to convert to open surgery. Early reports of procedural success rates are likely to have 
been affected by operator learning-curve effects. Cribier et al. (2002) reported that, using the 
antegrade transvenous approach, 22 out of 26 implants (84.6%) were successfully deployed, 
with four failures due to technical complications. Failures occurred as a consequence of 
valve migration immediately after the procedure (n = 2) and poor tolerance of the guide 
wire across the mitral valve (n = 2). This high rate of technical achievement could not be 
replicated by other researchers using transvenous access due to the complexity of passing 
the guide wire through the interventricular septum and mitral valve. 
The introduction of retrograde methods for accessing the diseased aortic valve has led to 
greater procedure reproducibility. Webb et al. (2007) initially reported outcomes for 
transfemoral TAVI using the Edwards prosthesis in 50 patients. The procedural success rate 
in this cohort was 86% (43 out of 50 patients), with failure associated with inability to pass 
the catheter through the iliac artery (n = 1) or across the aortic valve (n = 3), device 
malpositioning (n = 2), or malfunction of the delivery system (n = 1). Other authors have 
demonstrated similar success rates for the transfemoral approach using the Edwards 
Lifesciences devices. Rodes-Cabau et al. (2008) successfully implanted TAVI prostheses in 
91% of their patients, with failure occurring as a result of severely calcified iliac disease (n = 1) 
and intra-operative death secondary to myocardial ischaemia (n = 1). Similarly, Descoutures 
et al. (2008) reported success in 10 out of 12 patients (83%). In this series, procedural failure 
was the consequence of an inability to cannulate the iliac vessels (n = 1) and of fatal 
hemopericardium due to left ventricular perforation by the guide wire (n = 1).  
Only Edwards Lifesciences devices are currently licensed for use using the transapical 
approach. Ye et al. (2009) and Zierer et al. (2008) both reported success rates of 100% in small 
case series using transapical access. In larger studies the success rates are similarly 
impressive. In a study by Walther et al. (2008) successful implantation was accomplished in 
47 out of 50 patients (94%), with three patients requiring conversion to open AVR. In 
another multicentre study by Walther et al, 55 out of 59 implants were deployed successfully 
with four patients requiring urgent sternotomy and AVR due to device malposition 
(Walther et al., 2007). In an article by Svensson et al. (2008), procedural success was 88% in 40 
patients undergoing transapical TAVI. Of the five patients in whom TAVI was deemed to 
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have failed, the etiological factors were valve embolization (n = 3), valve migration (n = 1), 
and paravalvular leak (n = 1). 
The Medtronic CoreValve system is licensed for use using only retrograde percutaneous 
methods, typically transfemoral. The feasibility outcomes for this device are excellent, with 
several studies reporting 100% success rates (Behan et al., 2008; Berry et al., 2007; De Jaegere 
et al., 2008). In a large prospective registry of 646 patients by Piazza et al. (2008), the 
procedural success rate was 97%. The authors did not present reasons for failure of 
implantation of the CoreValve device. In a small study, Grube et al. (2006) achieved 
successful implantation of TAVI prostheses in 21 out of 25 patients (84%). Reasons for 
procedural failure included paravalvular leak (n = 2), inability to cross a heavily calcified 
aortic valve (n = 1), and sudden death during balloon valvuloplasty (n = 1). In a second 
multicenter study by Grube et al. (2007), the procedural success rate was comparatively low 
(74%), which appears to be the consequence of malpositioning of a significant number of 
implants. Tamburino et al. (2009) reported outcomes for 30 patients treated with CoreValve 
TAVI. The procedural success rate was 93%, with one incident of pericardial tamponade and 
one of malpositioning of the TAVI device necessitating VIV implantation. It can be 
concluded from these reports that TAVI is a feasible procedure and that success rates are 
likely to improve with greater operator experience and more advanced devices. 
4.3 Safety of TAVI 
The assessment of safety in cardiothoracic surgery is made through reporting 30-day major 
adverse cardiovascular and cerebrovascular events (MACCE). Thirty-day mortality is 
conventionally defined as the occurrence of death from any cause within 30 days of a 
procedure. However, definitions are sometimes heterogeneous and must be considered 
carefully when outcomes from multiple studies are combined. In the case of TAVI, 30-day 
mortality is generally favorable and ranges from 0% to 25% (Behan et al., 2008; Berry et al., 
2007; Cribier et al., 2002; De Jaegere et al., 2008; Descoutures et al., 2008; Grube et al., 2006; 
Grube et al., 2007; Piazza et al., 2008; Rodes-Cabau et al., 2008; Spargias et al., 2008; Svensson 
et al., 2008; Tamburino et al., 2009; Walther et al., 2007; Walther et al., 2008; Webb et al., 2007; 
Ye et al., 2009; Zierer et al., 2008). Thirty-day mortality rates appear to be similar between the 
different devices and between transapical and transfemoral access routes. 
Vascular complications are one of the major concerns with percutaneous approaches. 
Vascular injury has been shown to occur in up to 18% of TAVI procedures and can lead to 
hemorrhage, limb ischemia, and amputation (Behan et al., 2008; Descoutures et al., 2008; 
Leon et al., 2010; Piazza et al., 2008; Rodes-Cabau et al., 2008; Spargias et al., 2008; Tamburino 
et al., 2009; Thomas et al., 2010; Webb et al., 2007; Zierer et al., 2008). The etiology of vascular 
damage is often attributed to the large-caliber sheaths used with early TAVI devices. It is 
envisaged that the introduction of low-profile introducers and greater operator experience 
will reduce vascular complications. In addition, percutaneous vessel closure devices for 
transfemoral access are now widely available and will contribute further to the reduction in 
periprocedural major hemorrhage. Onsite access to vascular surgeons and interventional 
radiologists with experience of open and endovascular repair of damaged vessels is 
encouraged. The team should be familiar with the use of crossover femoral cannulation, 
covered stents and balloon tamponade to control bleeding vessels. 
Stroke and transient ischemic attacks (TIAs) are common sequelae of TAVI deployment 
(range: 0% to 10%) and are believed to be the consequence of atheromatous emboli from the 
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ascending aorta and diseased aortic valve (Berry et al., 2007; Cribier et al., 2002; Descoutures 
et al., 2008; Grube et al., 2006; Grube et al., 2007; Leon et al., 2010; Piazza et al., 2008; Rodes-
Cabau et al., 2008; Svensson et al., 2008; Tamburino et al., 2009; Thomas et al., 2010; Walther et 
al., 2007; Webb et al., 2007; Ye et al., 2009; Zierer et al., 2008). The risk of cerebrovascular 
events is increased in TAVI patients with atrial fibrillation and in those in whom valve 
thrombosis has occurred. Diffusion-weighted magnetic resonance imaging has 
demonstrated new cerebral lesions in up to 91% of patients undergoing TAVI (Ghanem et 
al., 2010; Kahlert et al., 2010). Fortunately, these radiological images do not correlate with 
clinically observed neurological deficits, which suggests that ischemic brain injury is 
predominantly subclinical (Lefevre et al., 2011; Webb et al., 2009a). The introduction of less 
traumatic delivery devices may help to reduce the incidence of cerebrovascular events, 
while novel catheters that are designed to capture or deflect emboli are under evaluation 
(Nietlispach et al., 2010). 
Occlusion of the left main coronary ostium is a potentially fatal complication of TAVI 
insertion. The usual mechanism involves upward displacement of the native aortic valve 
leaflet such that it completely covers the coronary ostia. Rarely, the device itself can abut 
against the coronary ostia, which reduces blood flow to the myocardium. Low coronary 
origin (less than 12 mm superior to the aortic annulus on computed tomography) or shallow 
coronary sinuses are thought to predispose to left main coronary artery occlusion (Tops et 
al., 2008; Webb, 2009b). The Medtronic CoreValve has a tampered proximal end, which is 
designed to prevent coronary occlusion. 
Bradycardia requiring a permanent pacemaker is a frequent problem following TAVI. It 
results from pressure effects on the conduction pathways that pass through the 
membranous interventricular septum beneath the aortic valve. This is particularly common 
in patients with a pre-existing bundle branch or atrioventricular block. Several additional 
factors are believed to predispose to pacemaker insertion: advanced age, oversizing of the 
implant, and the depth of the implant within the LV outflow tract (Willson & Webb, 2011). 
The Medtronic CoreValve is considerably longer than the Edwards SAPIEN and is in 
contact with a larger area of the interventricular septum. The CoreValve device is associated 
with considerably higher rates of pacemaker insertion (range: 20% to 38%) (Elchaninoff et al., 
2011; Jilaihawi et al., 2010; Piazza et al., 2010; Zahn et al., 2011) compared to the Edwards 
SAPIEN (range 3% to 10%) (Elchaninoff et al., 2011; Thomas et al., 2010; Webb et al., 2009a). 
Although valvular aortic regurgitation is rare after TAVI, paravalvular leak occurs more 
commonly and is moderate or severe in up to 15% of patients (Leon et al., 2010; Sherif et al., 
2010; Webb et al., 2009a; Zahn et al., 2011). Leak occurs when there is an inadequate seal 
between the outer surface of the device and the aortic annulus, which allows blood to flow 
around the periphery of the prosthesis. This may occur if the implant is deployed either too 
proximally or too distally in relation to the plane of the aortic annulus; when the chosen 
device is undersized in relation to the aortic annulus; or if the prosthesis fails to expand 
completely. Acute paravalvular leak can be treated with balloon valvuloplasty, retrieval of 
the device (if possible), or VIV techniques. TAVI has been shown to be associated with a 
higher incidence of paravalvular leak than open AVR (12% vs. 1%) (Leon et al., 2010). 
Acute renal impairment, defined as a glomerular filtration rate reduction of greater than 
25%, is associated with a four-fold increase in 30-day mortality following TAVI (Willson & 
Webb, 2011). Acute renal impairment and renal replacement therapy occur in 11% and 1.4% 
of TAVI patients, respectively, with risk factors including chronic kidney disease, blood 
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transfusion, hypertension, chronic obstructive pulmonary disease, and transapical access 
(Bagur et al., 2010). In patients with chronic kidney disease, the incidence of acute renal 
impairment is lower in those treated with TAVI than with open AVR (9% vs. 26%, p < 0.001) 
(Bagur et al., 2010), which perhaps reflects the deleterious effects of cardiopulmonary 
bypass, hypotension, and ischemia associated with open surgery. TAVI may therefore be a 
safer therapeutic option for AS patients with a history of chronic renal impairment. 
Open AVR in the presence of severe LV dysfunction is high-risk, and TAVI may be an 
appropriate alternative in this situation. A recent nonrandomized study (Clavel et al., 2010) 
compared TAVI (n = 83) to open AVR (n = 200). Despite a higher STS-PROM score in 
patients who received TAVI, the authors reported that TAVI was associated with a greater 
improvement in ejection fraction than open AVR (14% vs. 7%; p < 0.001) and better 
hemodynamics at one year. Evidence from randomized trials is required to assess whether 
TAVI results in better recovery of LV function than does AVR. 
Other complications associated with TAVI include: supraventricular tachyarrhythmia 
(range: 5% to 31%); ventricular tachyarrhythmia (range: 0% to 4%); myocardial infarction 
(range: 0% to 15%); cardiac tamponade (range: 2% to 10%); conversion to open surgery 
(range: 0% to 8%); conversion to valvuloplasty (range: 0% to 4%); emergency valve-in-valve 
procedure (range: 2% to 12%); and aortic dissection or rupture (range: 0% to 4%) (Behan et 
al., 2008; Berry et al., 2007; Cribier et al., 2002; De Jaegere et al., 2008; Descoutures et al., 2008; 
Grube et al., 2006; Grube et al., 2007; Piazza et al., 2008; Rodes-Cabau et al., 2008; Spargias et 
al., 2008; Svensson et al., 2008; Tamburino et al., 2009; Walther et al., 2007; Walther et al., 2008; 
Webb et al., 2007; Ye et al., 2009; Zierer et al., 2008). The overall 30-day MACCE ranges from 
3% to 35% (Behan et al., 2008; Berry et al., 2007; Cribier et al., 2002; De Jaegere et al., 2008; 
Descoutures et al., 2008; Grube et al., 2006; Grube et al., 2007; Piazza et al., 2008; Rodes-Cabau 
et al., 2008; Spargias et al., 2008; Svensson et al., 2008; Tamburino et al., 2009; Walther et al., 
2007; Walther et al., 2008; Webb et al., 2007; Ye et al., 2009; Zierer et al., 2008). 
4.4 Efficacy of TAVI 
The efficacy of valvular procedures can be determined by whether they improve 
echocardiographic measurements of hemodynamic performance and by the effect of 
treatment on patient function and quality of life. The main pathological findings at 
echocardiography in patients with severe AS are reduced AVA, raised peak and mean 
pressure gradients across the aortic valve, reduced LV ejection fraction, and LV dysfunction. 
Numerous studies have investigated the echocardiographic outcomes of TAVI and have 
consistently demonstrated statistically significant (p < 0.05) improvements in AVA, mean 
and peak aortic valve pressure gradients, and LV ejection fraction between preoperative and 
early postoperative values (Behan et al., 2008; Berry et al., 2007; Clavel et al., 2009; Cribier et 
al., 2002; De Jaegere et al., 2008; Descoutures et al., 2008; Figulla et al., 2011; Grube et al., 2006; 
Grube et al., 2007; Piazza et al., 2008; Rodes-Cabau et al., 2008; Spargias et al., 2008; Svensson 
et al., 2008; Tamburino et al., 2009; Walther et al., 2007; Walther et al., 2008; Webb et al., 2007; 
Ye et al., 2009; Zierer et al., 2008). Furthermore, there is no deterioration in echocardiographic 
outcomes in patients followed-up for at least a year, which suggests that TAVI produces 
longer-lasting effects than balloon valvuloplasty alone (Cribier et al., 2002; Figulla et al., 2011; 
Webb et al., 2007; Ye et al., 2009). 
It is imperative that improvements in hemodynamics translate into tangible benefits to 
patient function and health status. In studies of cardiothoracic surgery, patient function and 
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the severity of symptoms are most commonly assessed through changes in NYHA 
classification. This clinician-reported outcome assigns patients to one of four categories, 
ranging from no symptoms or limitations on ordinary physical activity (Class I) to severe 
symptoms at rest necessitating continuous bed rest (Class IV). TAVI has been shown 
consistently to improve NYHA classification, with between 50% and 100% of patients 
demonstrating an improvement of at least one grade in NYHA classification at one-month 
post-procedure (Cribier et al., 2002; Gotzmann et al., 2010; Grube et al., 2006; Grube et al., 
2007; Rodes-Cabau et al., 2008; Spargias et al., 2008; Svensson et al., 2008; Webb et al., 2007; Ye 
et al., 2009). The short duration of follow-up of most studies means that it is difficult to 
determine whether these benefits are sustained, but some publications have reported that 
functional improvements last at least a year (Leon et al., 2010; Webb et al., 2009a). NYHA 
classification is also correlated with performance in the 6-minute walk test (Demers et al., 
2001; Gotzmann et al., 2010). 
Patient-reported outcomes (PROs), including health-related quality of life, provide unbiased 
assessments of health status from the patient’s perspective. Instruments (most often 
questionnaires) designed to capture these issues are called HRQL tools and are 
multidimensional, encompassing perceptions of physical, emotional, and social function, as 
well as assessing specific symptoms caused by the disease and treatment (Fayers & Hays., 
2005). The development of symptoms of congestive cardiac failure confers a poor prognosis 
on patients with severe AS and is likely to significantly affect HRQL. It is important to 
determine whether TAVI has a beneficial effect on HRQL and symptom palliation, in 
addition to increasing survival. Several studies have reported HRQL outcomes in patients 
treated with TAVI. Gotzmann et al., (2010) reported that HRQL (assessed using the 
Minnesota Living with Heart Failure Questionnaire [MLHFQ]) was significantly better 30 
days after TAVI when compared to baseline. This correlated with observed improvements 
in the 6-minute walk test and a reduction in serum beta-natriuretic peptide. Krane et al. 
(2010) measured HRQL with the Medical Outcomes Study Short Form-36 (SF-36) in a cohort 
of 99 patients treated with TAVI. Physical functioning, bodily pain, general health, and 
vitality all improved significantly from baseline at the three-month follow-up. Scores for 
social functioning and mental health remained static, while only role-emotional functioning 
deteriorated after TAVI. Ussia et al. (2009) used the SF-12 to compare HRQL in patients 
before and after TAVI with aged matched population reference values. Preprocedural AS 
patients had markedly worse HRQL than the general population for both physical and 
mental function. Five months after TAVI, HRQL had improved dramatically and was 
similar to that in the general population. This suggests that recovery following TAVI does 
occur, but takes several months. In the REVIVAL II feasibility study, HRQL was measured 
using the SF-12 and the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 30 days and 
6 months after TAVI insertion in 75 patients (Reynolds et al., 2008). At 30 days, a significant 
improvement in KCCQ score was observed, but not in the physical or mental functioning 
scales of the SF-12. However, by the 6-month follow-up, improvements in all facets of HRQL 
were evident. Taken together, these results provide strong evidence that TAVI improves 
HRQL in patients with severe AS, although it takes up to 6 months for HRQL to match that 
in the general population. 
4.5 Durability of TAVI 
TAVI is a relatively new intervention, and long-term outcome data is scarce beyond one 
year of follow-up. A recent systematic review (Figulla et al., 2011) incorporating pooled data 
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from multiple studies reported that mean one-year survival after TAVI was 75.9% (range: 
64.1% to 87.0%) (Al-Attar et al., 2009; Grube et al., 2008; Himbert et al., 2009; Kapadia et al., 
2009; Otten et al., 2009; Rajani et al., 2010; Rodes-Cabau et al., 2010; Thielmann et al., 2009; 
Walther et al., 2010; Webb et al., 2009a; Ye et al., 2009). In contrast the mean one-year survival 
rate for patients treated with medical care alone was 62.4% (range: 40.0% to 84.8%; p < 0.01 
vs. TAVI), revealing a 13.5% survival advantage in favor of TAVI at one year. This is in 
agreement with the PARTNER Trial, which reported a 20% survival advantage for TAVI 
(Leon et al., 2010). Gurvitch et al.  (2010) are one of the few groups to report outcomes for 
TAVI beyond one year of follow-up: In a cohort of 70 patients undergoing TAVI, they 
reported one-, two-, and three-year survival rates of 81%, 74%, and 61%, respectively, 
although patients who died within 30-days or in whom TAVI failed were excluded from the 
analysis. During the follow-up period, there were 30 late deaths, of which three were valve-
related: two patients died from intracerebral hemorrhage secondary to supratherapeutic 
anticoagulation, and sudden death occurred in another patient who was found postmortem 
to have an overgrowth of fibrous connective tissue around the prosthesis. No deaths were 
directly related to valvular dysfunction, which is in agreement with other studies reporting 
outcomes up to one year (Grube et al., 2008; Rodes-Cabau., 2010; Webb et al., 2009a). 
In the review by Figulla et al. (2011), one-year survival following transfemoral TAVI (79.2%, 
range: 68.1% to 87.0%) was superior to transapical access (73.6%, range 60.0% to 78.0%, p = 
0.04). Reduced survival in patients receiving transapical TAVI may be explained by the need 
for general anesthesia, thoracotomy, and cannulation of the left ventricular apex. It is 
important to note that most studies included in Figulla et al. were retrospective and 
nonrandomized, and consequently at risk of bias. RCTs are required to determine which 
method of gaining access to the diseased aortic valve is the most efficacious when 
undertaking TAVI. 
Very little is known about the risk of valvular degeneration with TAVI devices. In vitro 
testing of the latest generation of Edwards SAPIEN/XT and Medtronic CoreValve devices 
suggests that durability in excess of 10 years can be expected (Willson & Webb., 2010). 
Because of the proven efficacy of open AVR, without long-term in vivo data, it is very 
unlikely that TAVI devices will be licensed for use in younger patients without 
comorbidities. Indeed, freedom from reoperation for valvular degeneration is greater than 
95% with modern surgical bioprostheses (Jamieson et al., 1995). The results of long-term 
follow-up will be required to answer this clinical question, but it is unlikely that TAVI will 
replace open AVR for the management of uncomplicated, severe AS. 
5. Future directions 
The evidence base for TAVI is rapidly evolving, and there has been a significant rise in the 
number of new publications over the last five years. Most eagerly awaited are the findings 
of Cohort A of the PARTNER Trial. This will provide insight into the comparative efficacy 
of TAVI and open AVR in high-risk patients with severe symptomatic AS. The results of this 
trial will have important implications for healthcare policy implementation and may mean 
greater financial provision for TAVI in high-risk patients. In addition, the two main techniques 
for accessing the aortic valve (transfemoral and transapical) will need to be compared in an 
RCT, especially given that pooled data suggests one-year survival is worse after transapical 
TAVI (Figulla et al., 2011). If this is proved to be the case, then the transapical approach may 
be restricted to patients in whom the transfemoral route is contraindicated. 
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Using TAVI in moderate- or low-risk patients is not currently justified, because it would be 
unethical to withhold access to open AVR with its proven efficacy. The results of long-term 
follow-ups (> 10 years) of high-risk patients will be necessary to assess the durability of 
TAVI implants and to inform decisions about their use in younger, fitter patients. Given the 
short life expectancy of patients denied open surgery, it is unlikely that sufficient data will 
be available in the foreseeable future to determine whether TAVI is appropriate in low-risk 
candidates. It is also worth noting that a number of new prostheses will undoubtedly 
emerge in the next decade and that they will require appropriate evaluation against existing 
gold standards. An RCT using the Medtronic CoreValve system is also anticipated to 
publish its findings in 2013. Once the feasibility, safety, efficacy, and durability of TAVI 
devices have been established, the onus will shift towards healthcare economic evaluation to 
identify the most cost-effective means of treating severe AS. It is certainly conceivable that 
minimally invasive techniques, such as TAVI, will prove cost-effective in the long-term. 
6. Conclusions 
Severe aortic stenosis has a poor prognosis once symptoms of congestive cardiac failure and 
angina develop. It is conventional wisdom that surgical AVR offers the best hope of 
symptom palliation and long-term survival. However, approximately one-third of patients 
with severe symptomatic AS are denied access to surgery because of comorbidities and high 
operative risk. The last decade has witnessed the introduction of transcatheter aortic valve 
implantation, a surgical innovation that permits percutaneous replacement of the diseased 
aortic valve without sternotomy and a cardiopulmonary bypass. TAVI remains in its 
infancy, yet it has demonstrated superior medium-term survival, fewer symptoms, and a 
better quality of life than medical care alone. Doubts persist over the durability of the 
implants, long-terms outcomes, and the relative efficacy compared with surgical AVR in 
high-risk patients. However, TAVI is set to continue to revolutionize the management of 
severe symptomatic aortic stenosis. 
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